Details of the Drug Combination

General Information of Drug Combination (ID: DC8TZKW)

Drug Combination Name
Lapatinib Gemcitabine
Indication
Disease Entry Status REF
Metastatic Pancreatic Cancer Phase 1 [1]
Component Drugs Lapatinib   DM3BH1Y Gemcitabine   DMSE3I7
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lapatinib
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Gastroesophageal junction adenocarcinoma 2B71 Approved [3]
Melanoma 2C30 Approved [3]
Lapatinib Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Inhibitor [9]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [9]
Eukaryotic elongation factor 2 kinase (eEF-2K) TT1QFLA EF2K_HUMAN Inhibitor [10]
------------------------------------------------------------------------------------
Lapatinib Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [12]
------------------------------------------------------------------------------------
Lapatinib Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [14]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [13]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [14]
------------------------------------------------------------------------------------
Lapatinib Interacts with 36 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Activity [15]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [16]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [17]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [17]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [17]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Activity [17]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [18]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Activity [15]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [19]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [20]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Decreases Expression [21]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Decreases Expression [21]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [21]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [19]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Decreases Activity [22]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Decreases Activity [23]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [24]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [15]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Activity [19]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Activity [19]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Activity [15]
DNA replication licensing factor MCM7 (MCM7) OT6FXC6K MCM7_HUMAN Decreases Expression [19]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [21]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [15]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [21]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [21]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [20]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [25]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Decreases Response To Substance [26]
HLA class II histocompatibility antigen, DQ alpha 1 chain (HLA-DQA1) OTC6GISG DQA1_HUMAN Increases ADR [27]
Zinc finger protein SNAI1 (SNAI1) OTDPYAMC SNAI1_HUMAN Decreases Response To Substance [28]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Metabolism [21]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Increases Metabolism [21]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Response To Substance [28]
Tenascin-X (TNXB) OTVBWAV5 TENX_HUMAN Increases ADR [27]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Increases ADR [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 36 DOT(s)
Indication(s) of Gemcitabine
Disease Entry ICD 11 Status REF
Anterior urethra cancer N.A. Approved [4]
Biliary tract cancer 2C17 Approved [4]
Carcinoma 2A00-2F9Z Approved [4]
Cervical cancer 2C77.0 Approved [4]
Cholangiocarcinoma 2C12.10 Approved [4]
Fallopian tube neoplasm N.A. Approved [4]
Gallbladder carcinoma N.A. Approved [4]
Leiomyosarcoma 2B58 Approved [4]
Leukemia N.A. Approved [4]
Lung cancer 2C25.0 Approved [4]
MALT lymphoma N.A. Approved [4]
Nodal marginal zone lymphoma 2A85.0 Approved [4]
Non-small-cell lung cancer 2C25 Approved [5]
Ovarian disorder N.A. Approved [4]
Ovarian neoplasm N.A. Approved [4]
Pancreatic adenocarcinoma N.A. Approved [4]
Pancreatic ductal carcinoma 2C10.0 Approved [4]
Pancreatic tumour 2C10 Approved [4]
Posterior urethra cancer N.A. Approved [4]
Recurrent adult burkitt lymphoma 2A85.6 Approved [4]
Solid tumour/cancer 2A00-2F9Z Approved [6]
Splenic marginal zone lymphoma N.A. Approved [4]
Urethral cancer 2C93 Approved [4]
Urinary bladder neoplasm N.A. Approved [4]
Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [7]
Severe acute respiratory syndrome (SARS) 1D65 Preclinical [7]
Colon cancer 2B90.Z Investigative [4]
Gemcitabine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ribonucleoside-diphosphate reductase M2 (RRM2) TTBWDI0 RIR2_HUMAN Modulator [35]
------------------------------------------------------------------------------------
Gemcitabine Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [36]
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [37]
Concentrative nucleoside transporter 1 (SLC28A1) DT0EQPW S28A1_HUMAN Substrate [38]
------------------------------------------------------------------------------------
Gemcitabine Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytidine aminohydrolase (CDA) DEKEDRC CDD_HUMAN Metabolism [39]
Uridine/cytidine monophosphate kinase (UMPK) DEMPH4I KCY_HUMAN Metabolism [40]
Cytidine deaminase (cdd) DETX3A5 CDD_ECOLI Metabolism [41]
Cytidine deaminase (cdd) DEFVABT CDD_KLEP7 Metabolism [41]
Cytidine deaminase (cdd) DEYILK4 E0TLJ6_MYCHH Metabolism [42]
------------------------------------------------------------------------------------
Gemcitabine Interacts with 244 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytidine deaminase (CDA) OT3HXP6N CDD_HUMAN Affects Response To Substance [33]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Expression [43]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2) OTOB6J6R RIR2_HUMAN Affects Response To Substance [34]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Affects Response To Substance [34]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [44]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [45]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [46]
NF-kappa-B inhibitor epsilon (NFKBIE) OTLAYEL9 IKBE_HUMAN Affects Expression [29]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) OTQ4W7MT TR11B_HUMAN Increases Expression [29]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Increases Expression [29]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) OT5I4Y9K PLCB_HUMAN Decreases Expression [29]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Increases Expression [29]
E3 ubiquitin-protein ligase Praja-2 (PJA2) OT45TMC4 PJA2_HUMAN Increases Expression [29]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2) OT6Y1QZN IRAK2_HUMAN Increases Expression [29]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [29]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) OTJKOMXE BNI3L_HUMAN Increases Expression [29]
Heterogeneous nuclear ribonucleoprotein Q (SYNCRIP) OTRNDZXB HNRPQ_HUMAN Decreases Expression [29]
Melanoma-associated antigen C1 (MAGEC1) OTHMFHH8 MAGC1_HUMAN Increases Expression [29]
Liprin-alpha-4 (PPFIA4) OTWXG0DO LIPA4_HUMAN Increases Expression [29]
Transcription factor Maf (MAF) OT1GR3IZ MAF_HUMAN Increases Expression [29]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [29]
Krueppel-like factor 8 (KLF8) OTUC5CDB KLF8_HUMAN Increases Expression [29]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Increases Expression [29]
Fibrinogen gamma chain (FGG) OT5BJSEX FIBG_HUMAN Affects Expression [29]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [29]
Keratin, type II cytoskeletal 8 (KRT8) OTTM4X11 K2C8_HUMAN Decreases Expression [29]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Increases Expression [29]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) OTXOQDSG IFIT1_HUMAN Increases Expression [29]
Transcriptional activator Myb (MYB) OTJH64IV MYB_HUMAN Increases Expression [29]
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Increases Expression [29]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [29]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3) OT2HZK5M GTR3_HUMAN Increases Expression [29]
Creatine kinase B-type (CKB) OTUCKOTT KCRB_HUMAN Decreases Expression [29]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [29]
Homeobox protein Hox-B2 (HOXB2) OTTD6HMV HXB2_HUMAN Increases Expression [29]
Fos-related antigen 2 (FOSL2) OT3MT9HJ FOSL2_HUMAN Decreases Expression [29]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Expression [29]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Increases Expression [29]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [29]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Increases Expression [29]
C-X-C motif chemokine 2 (CXCL2) OTEJCYMY CXCL2_HUMAN Increases Expression [29]
C-X-C motif chemokine 3 (CXCL3) OTSL94KH CXCL3_HUMAN Increases Expression [29]
Endothelin-2 (EDN2) OTQ7RCPI EDN2_HUMAN Decreases Expression [29]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Increases Expression [29]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Increases Expression [29]
Prostaglandin G/H synthase 1 (PTGS1) OTHCRLEC PGH1_HUMAN Decreases Expression [29]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [29]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [29]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Increases Expression [29]
Protein EVI2B (EVI2B) OT98X1OE EVI2B_HUMAN Decreases Expression [29]
Heat shock 70 kDa protein 1-like (HSPA1L) OTC2V1K6 HS71L_HUMAN Decreases Expression [29]
Glutaredoxin-1 (GLRX) OT0QHTAR GLRX1_HUMAN Increases Expression [29]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [29]
Nicotinamide N-methyltransferase (NNMT) OTFM38GU NNMT_HUMAN Increases Expression [29]
B-cell lymphoma 6 protein (BCL6) OTQAWWO1 BCL6_HUMAN Increases Expression [29]
Regulator of G-protein signaling 2 (RGS2) OT0FSRW7 RGS2_HUMAN Increases Expression [29]
Leukemia inhibitory factor receptor (LIFR) OT36W9O5 LIFR_HUMAN Increases Expression [29]
Melanoma-associated antigen 10 (MAGEA10) OTI4KPYB MAGAA_HUMAN Decreases Expression [29]
Lysophosphatidic acid receptor 6 (LPAR6) OT4BY3W4 LPAR6_HUMAN Decreases Expression [29]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1) OTZRWTGA IQGA1_HUMAN Increases Expression [29]
Retinaldehyde dehydrogenase 3 (ALDH1A3) OT1C9NKQ AL1A3_HUMAN Increases Expression [29]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Increases Expression [29]
ETS translocation variant 1 (ETV1) OT6PMJIK ETV1_HUMAN Increases Expression [29]
Glypican-3 (GPC3) OTWS8WSW GPC3_HUMAN Increases Expression [29]
Transcription initiation factor IIA subunit 1 (GTF2A1) OTWW4PN0 TF2AA_HUMAN Affects Expression [29]
Growth arrest-specific protein 1 (GAS1) OTKJXG52 GAS1_HUMAN Decreases Expression [29]
Puromycin-sensitive aminopeptidase (NPEPPS) OTMENFXR PSA_HUMAN Decreases Expression [29]
Methionine--tRNA ligase, cytoplasmic (MARS1) OTLJ6MHJ SYMC_HUMAN Increases Expression [29]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Affects Expression [29]
Ras-related protein Rab-8A (RAB8A) OTPB54Y3 RAB8A_HUMAN Decreases Expression [29]
Lysozyme C (LYZ) OTD7H0G6 LYSC_HUMAN Decreases Expression [29]
Transforming growth factor beta-2 proprotein (TGFB2) OTC0TXEP TGFB2_HUMAN Increases Expression [29]
Large ribosomal subunit protein eL37 (RPL37) OTB6SDZ1 RL37_HUMAN Increases Expression [29]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Decreases Expression [29]
C-C motif chemokine 20 (CCL20) OTUCJY4N CCL20_HUMAN Increases Expression [29]
ADP-ribosylation factor 1 (ARF1) OT5C4C3L ARF1_HUMAN Decreases Expression [29]
Nuclear factor NF-kappa-B p100 subunit (NFKB2) OTS231V7 NFKB2_HUMAN Affects Expression [29]
Methylmalonate-semialdehyde/malonate-semialdehyde dehydrogenase , mitochondrial (ALDH6A1) OT8LCZCT MMSA_HUMAN Increases Expression [29]
Pro-neuregulin-1, membrane-bound isoform (NRG1) OTZO6F1X NRG1_HUMAN Increases Expression [29]
Tyrosine-protein phosphatase non-receptor type 11 (PTPN11) OTFH9M73 PTN11_HUMAN Affects Expression [29]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Decreases Expression [29]
ATP-dependent RNA helicase A (DHX9) OT5AAOQI DHX9_HUMAN Decreases Expression [29]
Nuclear cap-binding protein subunit 1 (NCBP1) OTYBR927 NCBP1_HUMAN Increases Expression [29]
TP53-binding protein 1 (TP53BP1) OTL8879S TP53B_HUMAN Increases Expression [29]
Ankyrin-3 (ANK3) OTJ3IRBP ANK3_HUMAN Increases Expression [29]
TNF receptor-associated factor 1 (TRAF1) OTTLM5RU TRAF1_HUMAN Affects Expression [29]
PDZK1-interacting protein 1 (PDZK1IP1) OTWA6M5K PDZ1I_HUMAN Increases Expression [29]
Treacle protein (TCOF1) OT4BOYTM TCOF_HUMAN Decreases Expression [29]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Affects Expression [29]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Increases Expression [29]
Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1) OTD1KRKO DYHC1_HUMAN Decreases Expression [29]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Increases Expression [29]
Interferon regulatory factor 3 (IRF3) OT81U8ME IRF3_HUMAN Decreases Expression [29]
FXYD domain-containing ion transport regulator 3 (FXYD3) OT9PPRHE FXYD3_HUMAN Increases Expression [29]
Ankyrin repeat domain-containing protein 1 (ANKRD1) OTHJ7JV9 ANKR1_HUMAN Increases Expression [29]
Disks large homolog 2 (DLG2) OTQ3BD8U DLG2_HUMAN Increases Expression [29]
Cysteine and glycine-rich protein 2 (CSRP2) OT4SW0HI CSRP2_HUMAN Increases Expression [29]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [29]
Golgi-associated kinase 1B (GASK1B) OT2HPHEI GAK1B_HUMAN Decreases Expression [29]
SUZ domain-containing protein 1 (SZRD1) OTJMEJWT SZRD1_HUMAN Decreases Expression [29]
Leucine-rich repeat-containing protein 28 (LRRC28) OTFTT6VN LRC28_HUMAN Increases Expression [29]
Mitochondrial basic amino acids transporter (SLC25A29) OT09PIFE S2529_HUMAN Increases Expression [29]
Equilibrative nucleobase transporter 1 (SLC43A3) OTR60ZLA S43A3_HUMAN Decreases Expression [29]
Proprotein convertase subtilisin/kexin type 9 (PCSK9) OTI0DU9Y PCSK9_HUMAN Increases Expression [29]
E3 ubiquitin-protein ligase RNF149 (RNF149) OT6SBKQV RN149_HUMAN Increases Expression [29]
F-box only protein 25 (FBXO25) OTDFA7F4 FBX25_HUMAN Increases Expression [29]
Solute carrier family 2, facilitated glucose transporter member 14 (SLC2A14) OTBFIOVY GTR14_HUMAN Increases Expression [29]
Membrane progestin receptor beta (PAQR8) OTGZ8W9F PAQR8_HUMAN Increases Expression [29]
Nuclear receptor subfamily 4 group A member 3 (NR4A3) OTPBE9R1 NR4A3_HUMAN Increases Expression [29]
La-related protein 4B (LARP4B) OT2HI0QE LAR4B_HUMAN Increases Expression [29]
Collagen triple helix repeat-containing protein 1 (CTHRC1) OTV88X2G CTHR1_HUMAN Increases Expression [29]
BTB/POZ domain-containing protein KCTD12 (KCTD12) OTPYKT4Z KCD12_HUMAN Decreases Expression [29]
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 (MAGI1) OTMV4ASV MAGI1_HUMAN Increases Expression [29]
Sialidase-1 (NEU1) OTH9BY8Y NEUR1_HUMAN Increases Expression [29]
Galactosylceramide sulfotransferase (GAL3ST1) OTSFFZRD G3ST1_HUMAN Decreases Expression [29]
Junctional adhesion molecule C (JAM3) OTX0F9QL JAM3_HUMAN Decreases Expression [29]
SLIT and NTRK-like protein 2 (SLITRK2) OTPVI22J SLIK2_HUMAN Increases Expression [29]
Anaphase-promoting complex subunit 1 (ANAPC1) OT2YY35L APC1_HUMAN Increases Expression [29]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Affects Expression [29]
Ras-related GTP-binding protein D (RRAGD) OTXLVWAH RRAGD_HUMAN Increases Expression [29]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Expression [29]
Intersectin-2 (ITSN2) OT8S0OO8 ITSN2_HUMAN Increases Expression [29]
Probable ribosome biogenesis protein RLP24 (RSL24D1) OT6KI56F RLP24_HUMAN Increases Expression [29]
Transcription elongation factor A protein-like 9 (TCEAL9) OT4UHDB5 TCAL9_HUMAN Increases Expression [29]
Histone deacetylase 9 (HDAC9) OTO8O0LF HDAC9_HUMAN Increases Expression [29]
Phosphoserine aminotransferase (PSAT1) OTVV1YV9 SERC_HUMAN Increases Expression [29]
Chloride intracellular channel protein 4 (CLIC4) OT6KTPKD CLIC4_HUMAN Increases Expression [29]
Alpha-2-macroglobulin (A2M) OTFTX90K A2MG_HUMAN Increases Expression [30]
Pro-epidermal growth factor (EGF) OTANRJ0L EGF_HUMAN Decreases Expression [30]
Insulin (INS) OTZ85PDU INS_HUMAN Increases Expression [30]
Lymphotoxin-alpha (LTA) OTUC3S76 TNFB_HUMAN Increases Expression [30]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [30]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Expression [30]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Decreases Expression [30]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [30]
Serum amyloid P-component (APCS) OT76JZ8Z SAMP_HUMAN Decreases Expression [30]
Beta-2-glycoprotein 1 (APOH) OTFMUX6O APOH_HUMAN Increases Expression [30]
Alpha-fetoprotein (AFP) OT9GG3ZI FETA_HUMAN Decreases Expression [30]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Decreases Expression [30]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [30]
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Increases Expression [30]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Expression [30]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [30]
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Decreases Expression [30]
Coagulation factor VII (F7) OTGNJ97M FA7_HUMAN Decreases Expression [30]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Increases Expression [30]
Granulocyte colony-stimulating factor (CSF3) OT9GC6TP CSF3_HUMAN Decreases Expression [30]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [30]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [30]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [30]
Prostatic acid phosphatase (ACP3) OTSIM0YG PPAP_HUMAN Decreases Expression [30]
Kit ligand (KITLG) OTB9AVQ4 SCF_HUMAN Decreases Expression [30]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Decreases Expression [30]
Brain-derived neurotrophic factor (BDNF) OTLGH7EW BDNF_HUMAN Decreases Expression [30]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [30]
Interleukin-13 (IL13) OTI4YS3Y IL13_HUMAN Increases Expression [30]
Thrombopoietin (THPO) OTO73DZ2 TPO_HUMAN Increases Expression [30]
Interleukin-15 (IL15) OTQSYWQS IL15_HUMAN Decreases Expression [30]
Leptin (LEP) OT5Q7ODW LEP_HUMAN Decreases Expression [30]
Pappalysin-1 (PAPPA) OTTTG9PG PAPP1_HUMAN Decreases Expression [30]
Pro-interleukin-16 (IL16) OTZ2MO6B IL16_HUMAN Increases Expression [30]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Increases Expression [30]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Decreases Expression [47]
Neurogenic locus notch homolog protein 1 (NOTCH1) OTI1WADQ NOTC1_HUMAN Increases Expression [47]
Proto-oncogene c-Rel (REL) OTTCKMAC REL_HUMAN Decreases Expression [47]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Activity [48]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [49]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Decreases Expression [50]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Decreases Expression [51]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [52]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Decreases Expression [45]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [53]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [54]
Zinc finger protein GLI2 (GLI2) OTIRV97L GLI2_HUMAN Affects Expression [45]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Increases Expression [55]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [45]
Serine/threonine-protein kinase B-raf (BRAF) OT7S81XQ BRAF_HUMAN Decreases Expression [45]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [53]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Affects Expression [43]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [56]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Affects Expression [45]
Cannabinoid receptor 1 (CNR1) OTEALO6G CNR1_HUMAN Increases Expression [57]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [58]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [46]
Aryl hydrocarbon receptor nuclear translocator (ARNT) OTMSIEZY ARNT_HUMAN Increases Expression [45]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [46]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Methylation [59]
Cannabinoid receptor 2 (CNR2) OTYP9P43 CNR2_HUMAN Increases Expression [57]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases Expression [60]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Increases Expression [45]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Activity [61]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [62]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [49]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3) OTI2OREX MP2K3_HUMAN Increases Phosphorylation [63]
Transcription factor SOX-2 (SOX2) OTFAWCAU SOX2_HUMAN Increases Expression [60]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [64]
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6) OTK13JKC MP2K6_HUMAN Increases Phosphorylation [63]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Decreases Expression [45]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [62]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Cleavage [65]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Affects Expression [45]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Decreases Expression [45]
POU domain, class 5, transcription factor 1 (POU5F1) OTDHHN7O PO5F1_HUMAN Decreases Expression [43]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Expression [66]
Regenerating islet-derived protein 3-alpha (REG3A) OT0BVQRB REG3A_HUMAN Decreases Expression [64]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [46]
Protein patched homolog 1 (PTCH1) OTMG07H5 PTC1_HUMAN Affects Expression [45]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [62]
Sonic hedgehog protein (SHH) OTOG2BXF SHH_HUMAN Decreases Expression [45]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [53]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Increases Expression [64]
Protein smoothened (SMO) OTXXE208 SMO_HUMAN Increases Expression [60]
Homeobox protein NANOG (NANOG) OTUEY1FM NANOG_HUMAN Decreases Expression [60]
Axin-2 (AXIN2) OTRMGQNU AXIN2_HUMAN Affects Expression [45]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Increases ADR [67]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Decreases Response To Substance [68]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Affects Response To Substance [69]
Splicing factor 45 (RBM17) OT9ROJCL SPF45_HUMAN Decreases Response To Substance [70]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Affects Response To Substance [71]
Neuropilin-1 (NRP1) OTCGULYV NRP1_HUMAN Decreases Response To Substance [72]
Oxysterol-binding protein 2 (OSBP2) OTDGLB4J OSBP2_HUMAN Increases ADR [67]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Decreases Response To Substance [73]
Equilibrative nucleoside transporter 3 (SLC29A3) OTGLX8XU S29A3_HUMAN Affects Transport [74]
Probable ATP-dependent RNA helicase DDX53 (DDX53) OTHK3EGZ DDX53_HUMAN Affects Response To Substance [75]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Decreases Response To Substance [76]
Pyruvate kinase PKM (PKM) OTLHHMC2 KPYM_HUMAN Affects Response To Substance [49]
Equilibrative nucleoside transporter 1 (SLC29A1) OTLOOZZS S29A1_HUMAN Increases Response To Substance [77]
Alpha-protein kinase 3 (ALPK3) OTLUYSMO ALPK3_HUMAN Increases ADR [67]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Increases Response To Substance [78]
Death-associated protein kinase 1 (DAPK1) OTNCNUCO DAPK1_HUMAN Increases ADR [79]
Cytochrome c oxidase subunit 3 (COX3) OTNNGBYJ COX3_HUMAN Decreases Response To Substance [80]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Decreases Response To Substance [81]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Increases ADR [82]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Affects Response To Substance [83]
3-phosphoinositide-dependent protein kinase 1 (PDPK1) OTT09ZVP PDPK1_HUMAN Decreases Response To Substance [84]
Nucleophosmin (NPM1) OTTBYYT0 NPM_HUMAN Decreases Response To Substance [85]
Serine/threonine-protein kinase SMG1 (SMG1) OTTS3SXE SMG1_HUMAN Decreases Response To Substance [86]
ATP-dependent DNA helicase PIF1 (PIF1) OTUHKKVP PIF1_HUMAN Decreases Response To Substance [56]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Response To Substance [87]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Increases ADR [88]
Olfactory receptor 4D6 (OR4D6) OTXJKUT1 OR4D6_HUMAN Affects Response To Substance [75]
PDZ domain-containing protein GIPC1 (GIPC1) OTXLVCPJ GIPC1_HUMAN Affects Response To Substance [89]
Integrin-linked protein kinase (ILK) OTYG2FD1 ILK_HUMAN Affects Response To Substance [69]
Poly polymerase 2 (PARP2) OTYL81ZI PARP2_HUMAN Decreases Response To Substance [90]
------------------------------------------------------------------------------------
⏷ Show the Full List of 244 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Metastatic Pancreatic Cancer DCSWME9 N. A. Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00447122) BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
3 Lapatinib FDA Label
4 Gemcitabine FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4793).
7 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
8 UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3. Chem Biol Interact. 2019 Sep 1;310:108745. doi: 10.1016/j.cbi.2019.108745. Epub 2019 Jul 9.
9 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
10 Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813.
11 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
12 The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
13 Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
14 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
15 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
16 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
17 P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
18 Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
19 CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
20 Effects of lapatinib on cell proliferation and apoptosis in NB4 cells. Oncol Lett. 2018 Jan;15(1):235-242. doi: 10.3892/ol.2017.7342. Epub 2017 Nov 3.
21 The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
22 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
23 Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.
24 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
25 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
26 The K-Ras effector p38 MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. J Biol Chem. 2017 Sep 8;292(36):15070-15079. doi: 10.1074/jbc.M117.779488. Epub 2017 Jul 24.
27 HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011 Feb 20;29(6):667-73. doi: 10.1200/JCO.2010.31.3197. Epub 2011 Jan 18.
28 Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. Int J Biochem Cell Biol. 2016 Feb;71:12-23. doi: 10.1016/j.biocel.2015.11.014. Epub 2015 Nov 28.
29 Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
30 Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010 Jun 29;103(1):52-60.
31 Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology. 2010;10(1):19-26. doi: 10.1159/000264680. Epub 2010 Mar 19.
32 XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas. 2006 Apr;32(3):288-96. doi: 10.1097/01.mpa.0000218314.67111.fb.
33 Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008 Sep 2;99(5):760-7. doi: 10.1038/sj.bjc.6604528.
34 14-3-3 regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. Oncotarget. 2016 Apr 5;7(14):17726-36. doi: 10.18632/oncotarget.7394.
35 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
36 Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70.
37 Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
38 Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017 Nov 16;9(11).
39 Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.
40 Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos. 2008 Sep;36(9):1951-9.
41 Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
42 Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
43 Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil. Toxicol Appl Pharmacol. 2022 Feb 15;437:115887. doi: 10.1016/j.taap.2022.115887. Epub 2022 Jan 19.
44 Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
45 A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
46 Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
47 Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 2011 Jan;19(1):188-95.
48 Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2. Cancer Biol Ther. 2006 Oct;5(10):1294-303. doi: 10.4161/cbt.5.10.3152. Epub 2006 Oct 4.
49 Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting -catenin signaling pathway. Chem Biol Interact. 2024 Jan 5;387:110816. doi: 10.1016/j.cbi.2023.110816. Epub 2023 Nov 22.
50 p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res. 2006 Jan 1;12(1):235-41. doi: 10.1158/1078-0432.CCR-05-1700.
51 The anthelmintic drug niclosamide induces GSK--mediated -catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. Cell Death Dis. 2022 Feb 3;13(2):112. doi: 10.1038/s41419-022-04573-7.
52 High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002 Jun;23(6):949-57. doi: 10.1093/carcin/23.6.949.
53 CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-B signaling pathway. Cell Biol Toxicol. 2023 Aug;39(4):1549-1560. doi: 10.1007/s10565-022-09746-w. Epub 2022 Aug 1.
54 Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene. 2007 May 17;26(23):3431-9. doi: 10.1038/sj.onc.1210129. Epub 2006 Dec 4.
55 Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 2009 Feb;103(3):384-90. doi: 10.1111/j.1464-410X.2008.08098.x. Epub 2008 Oct 24.
56 Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage. J Appl Toxicol. 2023 Oct;43(10):1522-1532. doi: 10.1002/jat.4494. Epub 2023 May 16.
57 Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011 Apr 28;2(4):e152. doi: 10.1038/cddis.2011.36.
58 Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Anticancer Drugs. 2007 Feb;18(2):179-85. doi: 10.1097/CAD.0b013e328010ef47.
59 Reversible epigenetic regulation of 14-3-3 expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1. Mol Pharmacol. 2014 Nov;86(5):561-9. doi: 10.1124/mol.114.092544. Epub 2014 Sep 4.
60 Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.
61 EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One. 2012;7(2):e31067. doi: 10.1371/journal.pone.0031067. Epub 2012 Feb 13.
62 Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther. 2002 Nov;1(13):1221-7.
63 Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun. 2004 Mar 26;316(1):71-7. doi: 10.1016/j.bbrc.2004.02.017.
64 Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J Gastroenterol. 2006 Mar 14;12(10):1597-602. doi: 10.3748/wjg.v12.i10.1597.
65 Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004 Mar 20;109(2):182-8. doi: 10.1002/ijc.11679.
66 Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells. Acta Pharmacol Sin. 2010 Jun;31(6):741-5. doi: 10.1038/aps.2010.54.
67 Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
68 RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003 Nov 21;311(3):786-92. doi: 10.1016/j.bbrc.2003.10.060.
69 RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res. 2005 May 1;11(9):3433-8. doi: 10.1158/1078-0432.CCR-04-1510.
70 Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
71 Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas. 2006 Apr;32(3):297-305. doi: 10.1097/00006676-200604000-00010.
72 Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer. 2005 Jul 25;93(2):233-41. doi: 10.1038/sj.bjc.6602663.
73 Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18.
74 Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22.
75 Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clin Cancer Res. 2016 Jan 15;22(2):366-73. doi: 10.1158/1078-0432.CCR-15-0964. Epub 2015 Sep 16.
76 Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci. 2010 Nov;101(11):2351-60. doi: 10.1111/j.1349-7006.2010.01671.x.
77 Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest. 2008 Jul;88(7):773-84. doi: 10.1038/labinvest.2008.40. Epub 2008 May 19.
78 Increased expression of transcription factor TFAP2 correlates with chemosensitivity in advanced bladder cancer. BMC Cancer. 2011 Apr 14;11:135. doi: 10.1186/1471-2407-11-135.
79 A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012 Apr;22(4):229-35. doi: 10.1097/FPC.0b013e32834e9eba.
80 An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone. Biochem Pharmacol. 2007 Jun 15;73(12):1927-38. doi: 10.1016/j.bcp.2007.03.014. Epub 2007 Mar 20.
81 Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011 Sep;122(3):641-7. doi: 10.1016/j.ygyno.2011.05.003. Epub 2011 Jun 8.
82 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
83 Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer. Mol Carcinog. 2014 Sep;53(9):744-52. doi: 10.1002/mc.22026. Epub 2013 May 16.
84 Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006 Sep;70(3):1045-52. doi: 10.1124/mol.106.023333. Epub 2006 Jun 16.
85 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
86 [Effect of inhibiting the expression of hSMG-1 on chemosensitivity of human non-small cell lung cancer H1299 cells]. Zhonghua Yi Xue Za Zhi. 2011 Mar 1;91(8):554-9.
87 A novel 3-dimensional culture system uncovers growth stimulatory actions by TGF in pancreatic cancer cells. Cancer Biol Ther. 2011 Aug 1;12(3):198-207. doi: 10.4161/cbt.12.3.15979. Epub 2011 Aug 1.
88 An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist. 2007 Jun;12(6):622-30. doi: 10.1634/theoncologist.12-6-622.
89 GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. PLoS One. 2014 Dec 3;9(12):e114409. doi: 10.1371/journal.pone.0114409. eCollection 2014.
90 Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15;70(20):7970-80. doi: 10.1158/0008-5472.CAN-09-4521. Epub 2010 Aug 26.